Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Nurses File DPH Complaint Over Use Of Life-Threatening Medical Devices At UC Irvine Medical Center
The California Nurses Association/National Nurses Organizing Committee announces that it filed a complaint with the California Department of Public Health (DPH), calling for an urgent investigation into the ongoing use of dozens of narcotic infusion pumps at the University of California Irvine Medical Center that have a history of failure, thereby exposing patients to a dangerous overdose of narcotics.
generic viagra online
Gene Transfer Technology May Lead To HIV Vaccine
A research team may have broken the impasse that has frustrated HIV vaccine researchers by using an unconventional approach that bypasses the usual vaccine development path. Using gene transfer technology to produces molecules that block infection, the scientists protected monkeys from infection by a virus closely related to HIV -- the simian immunodeficiency virus, or SIV. "We used a leapfrog strategy, bypassing the natural immune system response that was the target of previous HIV and SIV vaccine candidates," explains study leader Philip R. Johnson, MD, chief scientific officer at The Children"s Hospital of Philadelphia and professor of pediatrics at the University of Pennsylvania. Johnson and colleagues reported their work in Nature Medicine Most attempts at developing an HIV vaccine have used substances aimed at stimulating the body"s immune system to produce antibodies that would eliminate the virus before or after it infected cells. In clinical trials, however, these vaccines have not elicited protective immune responses, just as the body fails on its own to produce an effective response during natural HIV infection.
News of the day
National Public Health Organizations Brief Capitol Hill On H1N1
The recent H1N1 flu outbreak served as a genuine test of our national public health system"s ability to respond to an emerging public health threat and experts are cautioning that a more severe outbreak could occur in the fall of 2009. Leaders from some of the nation"s foremost public health and medical associations will conduct a briefing for staff members from House and Senate offices on Thursday, May 21, 2009. Speakers will focus on the status of the current public health workforce and efforts needed to sustain workforce capacity to respond to emerging infectious diseases.
Diagnostics

CSL Biotherapies Starts Shipment Of Seasonal Influenza Vaccine For The 2009-2010 Flu Season

CSL Biotherapies, a subsidiary of one of the world"s leading manufacturers of thimerosal-free seasonal influenza vaccine, announced that it has begun shipment of its seasonal influenza virus vaccine to a national network of U.S. distributors for the 2009-2010 season. CSL Biotherapies plans to deliver more than eight million doses of the vaccine, the majority of which will be in single-dose, thimerosal-free, pre-filled syringes. CSL Biotherapies" seasonal flu vaccine is indicated for the active immunization of persons age 18 years and older against influenza disease (commonly referred to as the "flu") caused by influenza virus subtypes A and type B present in the vaccine. "CSL Biotherapies" early delivery of seasonal influenza vaccine to the U.S. clearly demonstrates our ability to rapidly optimize vaccine production in order to meet evolving public health needs," said Paul Perreault, President of CSL Biotherapies. "Working with the U.S. government, we are also moving quickly to develop a vaccine to address the H1N1 pandemic. Together, these efforts illustrate the expertise in influenza vaccine development and manufacturing that CSL has so successfully accumulated over the past 40 years." CSL Limited, the parent company of CSL Biotherapies, is the first vaccine manufacturer to initiate human clinical trials of the H1N1 influenza vaccine. First administration in healthy volunteers of CSL"s experimental H1N1 pandemic vaccine began on July 22 , 2009 in Australia. U.S. clinical studies are expected to commence in mid-August. CSL Biotherapies


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009